Healthcare provider profile · identity verified

Brian Phillip Williams, MD

Allopathic & Osteopathic Physicians|Family Medicine · ROCK HILL, SC · NPI 1093166548

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Brian Phillip Williams, MD received $220.82 in general payments during 2025 across 2 reported records.

AstraZeneca Pharmaceuticals LP accounted for 54.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$220.82

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$120.18	54.4%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$100.64	45.6%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$220.82	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$120.18	1	2025
Source payment records 2025-05-20 · AstraZeneca Pharmaceuticals LP · $120.18 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	35	11
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	27	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	134	27
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	609	194
Omeprazole	Omeprazole	490	159
Amlodipine Besylate	Amlodipine Besylate	443	161
Levothyroxine Sodium	Levothyroxine Sodium	405	109
Lisinopril	Lisinopril	333	101
Losartan Potassium	Losartan Potassium	316	98
Alprazolam	Alprazolam	303	57
Gabapentin	Gabapentin	271	99
Rosuvastatin Calcium	Rosuvastatin Calcium	250	80
Tramadol Hcl	Tramadol Hcl	229	50
Metformin Hcl	Metformin Hcl	227	72
Pantoprazole Sodium	Pantoprazole Sodium	204	75
Trazodone Hcl	Trazodone Hcl	185	64
Hydrochlorothiazide	Hydrochlorothiazide	183	61
Allopurinol	Allopurinol	180	55
Metoprolol Succinate	Metoprolol Succinate	168	59
Pravastatin Sodium	Pravastatin Sodium	163	50
Simvastatin	Simvastatin	157	47
Clonazepam	Clonazepam	145	28
Fluticasone Propionate	Fluticasone Propionate	138	56
Meloxicam	Meloxicam	134	51
Ozempic	Semaglutide	134	27
Furosemide	Furosemide	127	48
Zolpidem Tartrate	Zolpidem Tartrate	123	33
Metformin Hcl Er	Metformin Hcl	119	42
Sertraline Hcl	Sertraline Hcl	119	37
Tamsulosin Hcl	Tamsulosin Hcl	117	41
Tizanidine Hcl	Tizanidine Hcl	117	50
Escitalopram Oxalate	Escitalopram Oxalate	116	36
Potassium Chloride	Potassium Chloride	115	44
Montelukast Sodium	Montelukast Sodium	113	40
Albuterol Sulfate Hfa	Albuterol Sulfate	107	43
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	92	26
Metoprolol Tartrate	Metoprolol Tartrate	92	37
Fluoxetine Hcl	Fluoxetine Hcl	91	29
Duloxetine Hcl	Duloxetine Hcl	89	34
Famotidine	Famotidine	87	35
Lorazepam	Lorazepam	87	19
Prednisone	Prednisone	87	59
Diclofenac Sodium	Diclofenac Sodium	82	26
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	78	17
Carvedilol	Carvedilol	75	24
Pregabalin	Pregabalin	71	27
Jardiance	Empagliflozin	68	20
Glipizide	Glipizide	67	25
Synthroid	Levothyroxine Sodium	64	17
Triamcinolone Acetonide	Triamcinolone Acetonide	63	29
Citalopram Hbr	Citalopram Hydrobromide	62	17
Venlafaxine Hcl Er	Venlafaxine Hcl	62	16
Fenofibrate	Fenofibrate	61	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	61	19
Mounjaro	Tirzepatide	61	12
Ezetimibe	Ezetimibe	56	17
Celecoxib	Celecoxib	53	18
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	53	25
Temazepam	Temazepam	53	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	53	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	51	49
Cephalexin	Cephalexin	51	38
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	51	20
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	48	14
Bupropion Xl	Bupropion Hcl	48	12
Chlorthalidone	Chlorthalidone	48	18
Olmesartan Medoxomil	Olmesartan Medoxomil	48	16
Oxycodone Hcl	Oxycodone Hcl	48	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	47	15
Glipizide Er	Glipizide	47	15
Valacyclovir	Valacyclovir Hcl	46	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	45	12
Glimepiride	Glimepiride	44	12
Ibuprofen	Ibuprofen	44	17
Quetiapine Fumarate	Quetiapine Fumarate	43	suppressed
Alendronate Sodium	Alendronate Sodium	41	16
Diazepam	Diazepam	41	suppressed
Paroxetine Hcl	Paroxetine Hcl	40	14
Amitriptyline Hcl	Amitriptyline Hcl	39	14
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	39	11
Clopidogrel	Clopidogrel Bisulfate	39	15
Fluconazole	Fluconazole	38	29
Ondansetron Odt	Ondansetron	38	23
Benazepril Hcl	Benazepril Hcl	36	11
Buspirone Hcl	Buspirone Hcl	36	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	36	32
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	36	12
Farxiga	Dapagliflozin Propanediol	35	11
Hydralazine Hcl	Hydralazine Hcl	35	11
Mirtazapine	Mirtazapine	35	15
Valsartan	Valsartan	34	13
Atenolol	Atenolol	33	suppressed
Eliquis	Apixaban	33	13
Eszopiclone	Eszopiclone	31	suppressed
Ropinirole Hcl	Ropinirole Hcl	30	suppressed
Warfarin Sodium	Warfarin Sodium	30	suppressed
Januvia	Sitagliptin Phosphate	28	11
Phenobarbital	Phenobarbital	27	suppressed
Symbicort	Budesonide/Formoterol Fumarate	27	suppressed
Azithromycin	Azithromycin	25	25
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	25	suppressed
Carisoprodol	Carisoprodol	24	suppressed
Nystatin	Nystatin	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Testosterone Cypionate	Testosterone Cypionate	24	suppressed
Baclofen	Baclofen	23	suppressed
Linzess	Linaclotide	23	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	23	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Estradiol	Estradiol	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Verapamil Er	Verapamil Hcl	22	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Triazolam	Triazolam	20	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	19	suppressed
Dexlansoprazole Dr	Dexlansoprazole	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Mupirocin	Mupirocin	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Hydrocortisone	Hydrocortisone	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Topiramate	Topiramate	17	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	16	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Finasteride	Finasteride	15	suppressed
Methylphenidate Er	Methylphenidate Hcl	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Ramipril	Ramipril	15	suppressed
Terbinafine Hcl	Terbinafine Hcl	15	12
Acyclovir	Acyclovir	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Telmisartan	Telmisartan	14	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	13	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Oxycontin	Oxycodone Hcl	13	suppressed
Prempro	Estrogen,con/M-Progest Acet	13	suppressed
Trivora-28	Levonorgestrel/Ethin.Estradiol	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Colchicine	Colchicine	12	suppressed
Depakote Er	Divalproex Sodium	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Levofloxacin	Levofloxacin	12	11
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Savella	Milnacipran Hcl	12	suppressed
Tiotropium Bromide	Tiotropium Bromide	12	suppressed
Dapagliflozin	Dapagliflozin Propanediol	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Humulin R	Insulin Regular, Human	11	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed
Naproxen	Naproxen	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$220.82 · 2 records	AstraZeneca Pharmaceuticals LP	AIRSUPRA	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error